Working… Menu

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03060720
Recruitment Status : Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : March 22, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Matthew B. Yurgelun, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : April 7, 2019
Estimated Study Completion Date : February 2022